Armistice Capital »

Aptevo Therapeutics shares owned by Armistice Capital

Quarter-by-quarter ownership of Aptevo Therapeutics shares owned by Armistice Capital from 13F filings

Historical chart of Armistice Capital investment in Aptevo Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Aptevo Therapeutics held by Armistice Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Aptevo Therapeutics by Armistice Capital

Quarter filed Position value Share count Share price at filing
2023-09-30 $408k 1.2M 0.33

More positions owned by Armistice Capital

Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Ishares Tr Russell 2000 Etf Put Option (IWM)
Argenx Se Sponsored Adr (ARGX)
Supernus Pharmaceuticals (SUPN)
Ptc Therapeutics I (PTCT)
Neurocrine Biosciences (NBIX)
Agios Pharmaceuticals (AGIO)
Biogen Idec (BIIB)
Colgate-Palmolive Company (CL)
Travere Therapeutics (TVTX)
Nevro (NVRO)
Amazon (AMZN)
Dentsply Sirona (XRAY)
Regeneron Pharmaceuticals (REGN)
Alphabet Cap Stk Cl A (GOOGL)

View all positions for Armistice Capital

Top funds holding Aptevo Therapeutics

Citadel Advisors
Schonfeld Strategic Advisors
Squarepoint Ops
Millennium Management
Vanguard Group
Cantor Fitzgerald, L. P.
Alyeska Investment Group
Two Sigma Securities
Franklin Resources
Divergent Wealth Advisors
Jpmorgan Chase & Co
Wells Fargo & Company
Pnc Financial Services
Advisor Group Holdings
Citigroup

View all funds holding Aptevo Therapeutics